Advertisement TetraLogic, Merck enter oncology clinical trial collaboration - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

TetraLogic, Merck enter oncology clinical trial collaboration

US-based biopharmaceutical firm TetraLogic Pharmaceuticals has entered into an oncology clinical study collaboration with Merck.

TetraLogic is focused on discovering and developing new small molecule therapeutics in oncology and infectious diseases.

As part of the deal, the two firms will conduct an initial Phase I dose-escalation study of birinapant in combination with Keytruda in patients with relapsed or refractory solid tumors.

TetraLogic’s SMAC-mimetic Birinapant and Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) target different elements of cancer’s block against the immune system.

The deal will see TetraLogic sponsor and fund the trial, which is expected to begin in late 2015, while Merck will provide Keytruda.

In order to collaboratively oversee the conduct of the trial, the companies have formed a Joint Development Committee.

Data from the trial will be used to determine the path for further clinical development of the combination.

TetraLogic president and chief executive officer Kevin Buchi said: "We are very excited to work with Merck to evaluate birinapant in combination with Keytruda.

"Both molecules are designed to help the body’s immune system better attack cancer cells, and we think the combination could be very promising."